Actinium Pharmaceuticals Inc. (Delaware) Common Stock (ATNM)
Stock · AMEX · Health Care
$1.11as of 10/16/2026
Price chart
Active signals
ATNM Signal Track Record
How signals performed across all stocks →What ATNM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume SpikeActive now | 36 | +0.1% | 50% | September 8, 2026 |
| Bollinger Band Breakout | 22 | -4.9% | 45% | September 8, 2026 |
| Bollinger Band Breakdown | 20 | -1.1% | 45% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -5.3% | 38% | September 29, 2026 |
| Any 20-session window (baseline) | -3.4% | 40% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as C…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 27
- Website
- www.actiniumpharma.com/
Fundamentals
- 1-day range
- $1.05$1.15
- Market cap
- $24.69M
- P/E (trailing)
- 2.95
- P/E (forward)
- -2.15
- EPS (trailing)
- $0.36
- Dividend yield
- —
- Beta
- 0.33
- Avg. volume
- 141.8K
- Dividend pay date
- August 11, 2020
How Actinium Pharmaceuticals Inc. (Delaware) Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 31, 2023 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Actinium Pharmaceuticals Inc. (Delaware) Common Stock Competitors
Chosen by industry and closest market cap.
- ATNMActinium Pharmaceuticals Inc. (Delaware) Common Stock$1.13▲ 6.60%Market cap $24.69MP/E 2.95$0.7351$1.74
- LGVNLongeveron Inc. Class A Common Stock$1.39▼ 7.33%Market cap $24.44MP/E —$1.69$12.3
- AYTUAytu BioPharma Inc. Common Stock$2.04▲ 1.49%Market cap $25.01MP/E —$1.8$3.07
- TXMDTherapeuticsMD Inc. Common Stock$1.9▼ 1.55%Market cap $24.19MP/E 135.01$1.03$2.95
- IGCIGC Pharma Inc. Common Stock$0.25▲ 0.00%Market cap $23.94MP/E —$0.235$0.4508
- TVRDTvardi Therapeutics Inc. Common Stock$1.01▼ 5.61%Market cap $23.02MP/E —$0.93$7.23
- OBXObsidian Therapeutics Inc. Common Stock$11.77▼ 3.52%Market cap $22.74MP/E —$11.79$49.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ATNM Actinium Pharmaceuticals Inc. (Delaware) Common Stock | $24.69M | 2.95 | $1.13 | ▲ 6.60% | $0.7351$1.74 |
| LGVN Longeveron Inc. Class A Common Stock | $24.44M | — | $1.39 | ▼ 7.33% | $1.69$12.3 |
| AYTU Aytu BioPharma Inc. Common Stock | $25.01M | — | $2.04 | ▲ 1.49% | $1.8$3.07 |
| TXMD TherapeuticsMD Inc. Common Stock | $24.19M | 135.01 | $1.9 | ▼ 1.55% | $1.03$2.95 |
| IGC IGC Pharma Inc. Common Stock | $23.94M | — | $0.25 | ▲ 0.00% | $0.235$0.4508 |
| TVRD Tvardi Therapeutics Inc. Common Stock | $23.02M | — | $1.01 | ▼ 5.61% | $0.93$7.23 |
| OBX Obsidian Therapeutics Inc. Common Stock | $22.74M | — | $11.77 | ▼ 3.52% | $11.79$49.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Nicholson, C. David · September 2, 2026 · Grant94.2K
- Nicholson, C. David · September 2, 2026 · Grant62.8K
- Shetty Ajit · September 2, 2026 · Grant92.4K
- Shetty Ajit · September 2, 2026 · Grant61.6K
- Almenoff June Sherie · September 2, 2026 · Grant27.0K
- Chell Jeffrey W. · September 2, 2026 · Grant92.4K
- Richard I. Steinhart · September 2, 2026 · Grant94.2K
- Richard I. Steinhart · September 2, 2026 · Grant62.8K
- Almenoff June Sherie · September 2, 2026 · Grant18.0K
- Sandesh Seth · September 2, 2026 · Grant1.13M
- Sandesh Seth · September 2, 2026 · Grant1.03M
- Sandesh Seth · September 2, 2026 · Grant753.6K
- Chell Jeffrey W. · September 2, 2026 · Grant61.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 5.26M
- Total value held
- $4.59M
- Institutional holders
- 52
- Unknown1.26M
- Unknown600.8K
- Unknown564.6K
- Unknown471.6K
- Unknown371.2K
- Unknown337.2K
- Unknown336.1K
- Unknown201.3K
- Unknown126.2K
- Unknown124.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Actinium Announces ATNM-400 Presentation and CFO Appointment
Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.
Actinium Announces ATNM-400 Presentation and CFO Appointment. Actinium Pharmaceuticals will present early phase 1 data for its ATNM‑400 radiotherapy at the EANM 2026 meeting. The study is the first human trial of a non‑PSMA targeting therapy for metastatic prostate cancer. The company also added Dr. Matt David as chief financial officer, expanding its leadership team. These developments come as the stock trades near its 10‑touch support level of $1.14 and shows a volume spike.